ALEC
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 03-25-2019 | 03-25-2019 | 03-25-2019 | 03-25-2019 | 03-25-2019 | 03-25-2019 | 03-25-2019 | 03-25-2019 | 03-25-2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Actual EPS | -1.48 | -1.48 | -1.48 | -1.48 | -1.48 | -1.48 | -1.48 | -1.48 | -1.48 |
| Consensus EPS | -0.29 | -0.29 | -0.29 | -0.29 | -0.29 | -0.29 | -0.29 | -0.29 | -0.29 |
| Estimated EPS | -0.29 | -0.29 | -0.29 | -0.29 | -0.29 | -0.29 | -0.29 | -0.29 | -0.29 |
| Number of Estimates | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| EPS Surprise | -$1.19 | -$1.19 | -$1.19 | -$1.19 | -$1.19 | -$1.19 | -$1.19 | -$1.19 | -$1.19 |
Stats
Summary
Sector:
Industry:
Short Interest ():
Ethical Flags
Longest drawdown: 41 trading days
From: 2019-04-12 To: 2019-06-12
Lowest Point:
Prevail Therapeutics Proposes IPO Terms
via: SeekingAlpha at 2019-06-13 07:46:25:000
Quick Take Prevail Therapeutics ( PRVL ) has filed to raise gross proceeds of $125 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing Adeno-Associated Virus-based [AAV-based] gene therapies for the treatment of serious neurodegenerative diseases… read more...
Alector: Targeted Therapies For Neurodegenerative Diseases
via: SeekingAlpha at 2019-05-20 08:38:53:000
Shares of Alector Inc ( ALEC ) have risen by just 6% from its February 2019 IPO price point of $19. At the time the company took in around $176 million in proceeds (not including underwriter option of 1,387,500 shares). Investment banks involved included Morgan Stanley, BofA Merill Lynch, … read more...
Alector: Targeted Therapies For Neurodegenerative Diseases
via: SeekingAlpha at 2019-05-20 08:38:53:000
Shares of Alector Inc ( ALEC ) have risen by just 6% from its February 2019 IPO price point of $19. At the time the company took in around $176 million in proceeds (not including underwriter option of 1,387,500 shares). Investment banks involved included Morgan Stanley, BofA Merill Lynch, … read more...
Alector: Targeted Therapies For Neurodegenerative Diseases
via: SeekingAlpha at 2019-05-20 08:38:53:000
Shares of Alector Inc ( ALEC ) have risen by just 6% from its February 2019 IPO price point of $19. At the time the company took in around $176 million in proceeds (not including underwriter option of 1,387,500 shares). Investment banks involved included Morgan Stanley, BofA Merill Lynch, … read more...
Alector misses by $0.15, misses on revenue
via: SeekingAlpha at 2019-05-13 12:21:34:000
Alector (NASDAQ: ALEC ): Q1 GAAP EPS of -$0.42 misses by $0.15 . More news on: Alector, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Alector misses by $0.15, misses on revenue
via: SeekingAlpha at 2019-05-13 12:21:34:000
Alector (NASDAQ: ALEC ): Q1 GAAP EPS of -$0.42 misses by $0.15 . More news on: Alector, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Alector misses by $0.15, misses on revenue
via: SeekingAlpha at 2019-05-13 12:21:34:000
Alector (NASDAQ: ALEC ): Q1 GAAP EPS of -$0.42 misses by $0.15 . More news on: Alector, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Cortexyme IPO Isn't Cheap
via: SeekingAlpha at 2019-05-06 13:59:37:000
Targeting a market that could reach $1.1 trillion by 2050, Cortexyme ( CRTX ) will probably interest institutional investors. Besides, the company appears to have sufficient equity financing to complete its Phase 2-3 clinical trial. In addition, the fact that Pfizer ( PFE ) is among the shareh… read more...
Cortexyme IPO Isn't Cheap
via: SeekingAlpha at 2019-05-06 13:59:37:000
Targeting a market that could reach $1.1 trillion by 2050, Cortexyme ( CRTX ) will probably interest institutional investors. Besides, the company appears to have sufficient equity financing to complete its Phase 2-3 clinical trial. In addition, the fact that Pfizer ( PFE ) is among the shareh… read more...
Cortexyme IPO Isn't Cheap
via: SeekingAlpha at 2019-05-06 13:59:37:000
Targeting a market that could reach $1.1 trillion by 2050, Cortexyme ( CRTX ) will probably interest institutional investors. Besides, the company appears to have sufficient equity financing to complete its Phase 2-3 clinical trial. In addition, the fact that Pfizer ( PFE ) is among the shareh… read more...
Dosing underway in early-stage study of Alector's AL001 in severe dementia
via: SeekingAlpha at 2019-04-17 12:35:22:000
Alector (NASDAQ: ALEC ) announces that the first patient with frontotemporal dementia (FTD)has been dosed in the Phase 1b portion of its INFRONT study assessing the safety of multiple doses of AL001, a monoclonal antibody designed to modulate a protein expressed by nerve cells call… read more...
Dosing underway in early-stage study of Alector's AL001 in severe dementia
via: SeekingAlpha at 2019-04-17 12:35:22:000
Alector (NASDAQ: ALEC ) announces that the first patient with frontotemporal dementia (FTD)has been dosed in the Phase 1b portion of its INFRONT study assessing the safety of multiple doses of AL001, a monoclonal antibody designed to modulate a protein expressed by nerve cells call… read more...
Dosing underway in early-stage study of Alector's AL001 in severe dementia
via: SeekingAlpha at 2019-04-17 12:35:22:000
Alector (NASDAQ: ALEC ) announces that the first patient with frontotemporal dementia (FTD)has been dosed in the Phase 1b portion of its INFRONT study assessing the safety of multiple doses of AL001, a monoclonal antibody designed to modulate a protein expressed by nerve cells call… read more...
Alector reports Q4 results
via: SeekingAlpha at 2019-03-26 12:18:29:000
Alector (NASDAQ: ALEC ): Q4 GAAP EPS of -$1.48. More news on: Alector, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Alector reports Q4 results
via: SeekingAlpha at 2019-03-26 12:18:29:000
Alector (NASDAQ: ALEC ): Q4 GAAP EPS of -$1.48. More news on: Alector, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Alector reports Q4 results
via: SeekingAlpha at 2019-03-26 12:18:29:000
Alector (NASDAQ: ALEC ): Q4 GAAP EPS of -$1.48. More news on: Alector, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Big Pharma, Green Trucks And Jobs Report (Stocks To Watch Podcast)
via: SeekingAlpha at 2019-03-03 02:30:34:000
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...
Big Pharma, Green Trucks And Jobs Report (Stocks To Watch Podcast)
via: SeekingAlpha at 2019-03-03 02:30:34:000
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...
Big Pharma, Green Trucks And Jobs Report (Stocks To Watch Podcast)
via: SeekingAlpha at 2019-03-03 02:30:34:000
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...
Stocks To Watch: Big Pharma, Green Trucks And Jobs Report
via: SeekingAlpha at 2019-03-02 04:01:09:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Time to look ahead after the market came off its best two-month run in years. The e… read more...
Alector: Addressing Neuroinflammation In Neurodegenerative Diseases With Potential For A Cure
via: SeekingAlpha at 2019-03-01 10:47:01:000
Alector ( ALEC ) was founded in 2013 and is based in South San Francisco, Calif. Data by YCharts (Alector, common stock price chart) IPO price= $19/share. 52-week price range= $15.55 - $22.50 Market cap= $1.35 billion Net amount raised from IPO: $163.4M. Cash reserves aft… read more...
U.S. IPO Weekly Recap: 2 Billion-Dollar Biotechs Cap A Mixed Week For Biotech IPOs
via: SeekingAlpha at 2019-02-09 11:13:47:000
In the second week after the SEC opened, we saw a number of launches and two billion-dollar biotechs, Alector (ALEC) and Gossamer Bio (GOSS), price their IPOs. Another biotech, Harpoon Therapeutics (HARP), along with three SPACs, also priced their IPOs. Alector, a Phase 1 biotech developing … read more...
U.S. IPO Weekly Recap: 2 Billion-Dollar Biotechs Cap A Mixed Week For Biotech IPOs
via: SeekingAlpha at 2019-02-09 11:13:47:000
In the second week after the SEC opened, we saw a number of launches and two billion-dollar biotechs, Alector (ALEC) and Gossamer Bio (GOSS), price their IPOs. Another biotech, Harpoon Therapeutics (HARP), along with three SPACs, also priced their IPOs. Alector, a Phase 1 biotech developing … read more...
U.S. IPO Weekly Recap: 2 Billion-Dollar Biotechs Cap A Mixed Week For Biotech IPOs
via: SeekingAlpha at 2019-02-09 11:13:47:000
In the second week after the SEC opened, we saw a number of launches and two billion-dollar biotechs, Alector (ALEC) and Gossamer Bio (GOSS), price their IPOs. Another biotech, Harpoon Therapeutics (HARP), along with three SPACs, also priced their IPOs. Alector, a Phase 1 biotech developing … read more...
U.S. IPO Weekly Recap: 2 Billion-Dollar Biotechs Cap A Mixed Week For Biotech IPOs
via: SeekingAlpha at 2019-02-09 11:13:47:000
In the second week after the SEC opened, we saw a number of launches and two billion-dollar biotechs, Alector (ALEC) and Gossamer Bio (GOSS), price their IPOs. Another biotech, Harpoon Therapeutics (HARP), along with three SPACs, also priced their IPOs. Alector, a Phase 1 biotech developing … read more...
Alector prices IPO at $19
via: SeekingAlpha at 2019-02-07 02:40:03:000
Alector (NASDAQ: ALEC ) prices its IPO of 9.25M shares of common stock at $19.00/share, for expected gross proceeds of $176M. More news on: Alector, Inc., Healthcare stocks news, Read more … read more...
Alector prices IPO at $19
via: SeekingAlpha at 2019-02-07 02:40:03:000
Alector (NASDAQ: ALEC ) prices its IPO of 9.25M shares of common stock at $19.00/share, for expected gross proceeds of $176M. More news on: Alector, Inc., Healthcare stocks news, Read more … read more...
Alector Announces Pricing of Initial Public Offering
via: Business Wire at 2019-02-06 19:59:00:000
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the pricing of its initial public offering of 9,250,000 shares of common stock to the public at $19.00 per sh… read more...
Alector Announces Pricing of Initial Public Offering
via: Business Wire at 2019-02-06 19:59:00:000
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the pricing of its initial public offering of 9,250,000 shares of common stock to the public at $19.00 per sh… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|